The Revolution in Cholesterol Management: Putting PCSK9 Inhibitors into Practice
The Revolution in Cholesterol Management: Putting PCSK9 Inhibitors into Practice
CLICK "BEGIN" TO EVALUATE SESSIONS, CLAIM CME, AND PRINT A CERTIFICATE OF ATTENDANCE OR CERTIFICATE OF PARTICIPATION.
Target Audience
This continuing medical education activity should be of substantial interest to endocrinologists and endocrine fellows, cardiologists, and other healthcare professionals caring for patients with lipid disorders including familial hypercholesterolemia.
Learning Objectives
Upon completion of this educational activity, learners will be better able to:
- Summarize the biology and genetic underpinnings of dyslipidemia as related to the LDL receptor and PCSK9
- Explain the results of IMPROVE-IT and FOURIER
- Assess the relative strengths and weaknesses of traditional (statins and ezetimibe) vs newer (PCSK9-I) cholesterol-lowering therapies to treat patients with familial hypercholesterolemia (FH)
- Evaluate strategies to optimize patient tolerance of and compliance to statin and ezetimibe treatment in FH and Diabetes Mellitus Type 2 (DM2)
- Incorporate PCSK9-I appropriately for further needed cholesterol lowering in high-risk patients
Additional Information
Attachment | Size |
---|---|
![]() | 2.06 MB |
DISCLOSURE POLICY
The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.
Available Credit
- 2.00 AMA PRA Category 1 Credits™
- 2.00 CME Certificate of Participation